RG 125

Drug Profile

RG 125

Alternative Names: AZD 4076; RG125

Latest Information Update: 08 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca; Regulus Therapeutics
  • Class Antisense oligonucleotides; MicroRNAs
  • Mechanism of Action MIRN103 microRNA modulators; MIRN107 microRNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 02 Aug 2017 Discontinued - Phase-II for Non-alcoholic fatty liver disease in USA (SC) (AstraZeneca pipeline, August 2017)
  • 02 Aug 2017 Discontinued - Phase-II for Non-alcoholic steatohepatitis in USA (SC) (AstraZeneca pipeline, August 2017)
  • 07 Jul 2017 Phase-II clinical trials in Non-alcoholic fatty liver disease in USA (SC) (AstraZeneca pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top